Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 98Lymphoma 79Burkitt Lymphoma 52Leukemia, Myeloid, Acute 51Myelodysplastic Syndromes 41Lymphoma, Non-Hodgkin 41Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Mantle-Cell 33Leukemia, Lymphocytic, Chronic, B-Cell 32Leukemia, Myeloid, Accelerated Phase 30Hodgkin Disease 29Lymphoma, Follicular 28Blast Crisis 27Graft vs Host Disease 26Congenital Abnormalities 26Myeloproliferative Disorders 25Leukemia, Myeloid, Chronic-Phase 25Multiple Myeloma 24Breast Neoplasms 23Lymphoma, B-Cell, Marginal Zone 22Leukemia, Myelomonocytic, Chronic 22Lymphoma, Large-Cell, Immunoblastic 21Primary Myelofibrosis 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 16Recurrence 15Neoplasms, Plasma Cell 15Dendritic Cell Sarcoma, Interdigitating 15Anemia, Refractory, with Excess of Blasts 15

Interventions

tempol 1ebselen 1Pantoprazole 1Methotrexate 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ototoxicity × Methotrexate × Clear all
NCT01848457 2020-03-16

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Children's Hospital of Philadelphia

Phase 2 Completed
13 enrolled 15 charts
Sarcoma

Ototoxicity, Neoplasms, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡